

Emulating a target trial of proton pump inhibitors and dementia risk using claims data



Nayeon Ahn, Michael Nolde, Alexander Günter, Florian Güntner, Roman Gerlach, Martin Tauscher, Ute Amann, Jakob Linseisen, Christa Meisinger, Ina-Maria Rückert-Eheberg, Sebastian-Edgar Baumeister

Angaben zur Veröffentlichung / Publication details:

Ahn, Nayeon, Michael Nolde, Alexander Günter, Florian Güntner, Roman Gerlach, Martin Tauscher, Ute Amann, et al. 2022. "Emulating a target trial of proton pump inhibitors and dementia risk using claims data." *European Journal of Neurology* 29 (5): 1335–43.
<https://doi.org/10.1111/ene.15284>.

ORIGINAL ARTICLE

Emulating a target trial of proton pump inhibitors and dementia risk using claims data

Nayeon Ahn^{1,2}  | Michael Nolde^{1,2}  | Alexander Günter³ | Florian Güntner³ | Roman Gerlach⁴ | Martin Tauscher⁴ | Ute Amann⁵ | Jakob Linseisen^{1,2,5} | Christa Meisinger² | Ina-Maria Rückert-Eheberg^{1,2,6} | Sebastian-Edgar Baumeister⁷

¹Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University Munich, Munich, Germany

²Chair of Epidemiology, University of Augsburg at University Hospital Augsburg, Augsburg, Germany

³AOK Bayern, Munich, Germany

⁴Association of Statutory Health Insurance Physicians in Bavaria (Kassenärztliche Vereinigung Bayerns, KVB), Munich, Germany

⁵Independent Research Group Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

⁶Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

⁷Institute of Health Services Research in Dentistry, University of Münster, Münster, Germany

Correspondence

Nayeon Ahn, University of Augsburg/
Ludwig-Maximilians-University Munich,
Stenglinstr. 2, 86156 Augsburg, Germany.
Email: Nayeon.Ahn@med.uni-augsburg.de

Funding information

This study was supported by the Innovation Committee at the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany (grant no. 01VSF18013). The funding agency played no role in the design, methods, data collection, analysis and preparation of this article

Abstract

Background and purpose: Understanding the adverse effects of proton pump inhibitors (PPIs) is important due to their widespread use, but the available evidence for an increased dementia risk amongst patients taking PPIs is inconclusive. The present study aimed to estimate the causal effect of PPIs on the risk of dementia by target trial emulation and time-varying exposure modeling.

Methods: Using claims data of 2,698,176 insured people of a large German statutory health insurer, a target trial was conceptualized in which individuals aged 40 years and older were classified as PPI initiators or non-initiators between 2008 and 2018, and were followed until diagnosis of dementia, death, loss to follow-up or end of study. Incidence of dementia (International Classification of Diseases 10 codes F00, F01, F03, F05.1, G30, G31.0, G31.1, G31.9 and F02.8+G31.82) was defined applying a 1-year lag window. Weighted Cox models were used to estimate the effect of PPI initiation versus non-initiation on dementia risk and weighted pooled logistic regression was used to estimate the effect of time-varying use versus non-use.

Results: In all, 29,746 PPI initiators (4.4%) and 26,830 non-initiators (1.3%) were diagnosed with dementia. Comparing PPI initiation with no initiation, the hazard ratio for dementia was 1.54 (95% confidence interval 1.51–1.58). The hazard ratio for time-dependent PPI use versus non-use was 1.56 (95% confidence interval 1.50–1.63). Differentiated subtypes, including unspecified dementia, Alzheimer's disease and vascular dementia, showed increased risk by PPI initiation and time-varying PPI use.

See commentary by B. Bégaud on page 1289.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Conclusions: This study suggests that PPI initiation and time-varying PPI use may increase overall dementia risk.

KEYWORDS

cognitive impairment, dementia, gastroesophageal reflux disease, proton pump inhibitors

INTRODUCTION

The effect of proton pump inhibitors (PPIs) as a gastric acid suppressant is well established, and they are frequently used to treat disorders characterized by excessive gastric acid production [1]. In recent years, however, observational studies examining the association between PPI intake and risk of dementia have yielded conflicting results [2–6] pointing out the necessity of randomized clinical trials (RCTs) to establish more robust causal evidence. Whilst prospective RCTs are the standard criterion of causal inference [7], performing RCTs to evaluate the effects of PPI intake on dementia risk is infeasible and costly given the long prodromal phase of dementia [8,9]. The issue of attrition by loss to follow-up is also challenging in RCTs with long-term follow-up [7,8].

Given that previous observational studies on the relationship between PPI use and dementia risk have shown contradictory results [2–6], systematic reviews have not achieved consensus either [10–12]. Whilst Wang et al. (2021) reported no association between dementia risk and the use of PPI with a hazard ratio (HR) of 0.98 (95% confidence interval [CI] 0.85–1.13) and high heterogeneity ($I^2 = 98.5\%$) in the largest meta-analysis [12], recent observational studies conducted in Spain and Taiwan reported an increased risk of dementia in PPI users [2,6]. In addition, a recent Swedish study added a possible underlying mechanism between PPI use and dementia risk, explaining that PPIs may cause cholinergic dysfunction, which is known as a driving force of dementia [13].

Several reasons might have caused discrepancies in previous studies. In many studies, all individuals who took PPIs during the study period were included without information on dose or duration, which could have introduced exposure misclassification and thus attenuated the effect estimate [14–16]. PPI intake was often assessed in proximity to onset of dementia without proper consideration of the prodromal phase of dementia [4,17], which could have introduced reverse causation because changes in PPI intake could have taken place due to the symptoms of undiagnosed dementia [8]. Although some studies avoided those limitations, few studies have considered potential bias from time-varying confounding [3,18].

Some of the aforementioned limitations can be avoided by conducting an observational study that mimics a clinical trial using clear inclusion criteria, enrollment period, active treatment phases and long-term follow-up [19,20]. In this study, the protocol of a target trial to estimate the effects of PPI initiation and time-varying PPI use on the risk of dementia was specified using claims data from a large health insurer in Bavaria, Germany [20,21].

MATERIALS AND METHODS

Study design and participants

This study used administrative claims data from the largest statutory health insurer in Bavaria, Germany (Allgemeine Ortskrankenkassen Bayern). The anonymized data contained the insured individuals' demographic and comprehensive healthcare information, including hospital admissions, outpatient visits, diagnostic codes and drug prescription details. The International Classification of Diseases (ICD-10) was used to define hospital and ambulatory diagnoses, and drug prescriptions were classified according to the Anatomical Therapeutic Chemical Classification (ATC system). Data between January 2008 and December 2018 were used. The present study has been approved by the ethics committee at the Ludwig-Maximilians-University of Munich. Since the data were anonymized and produced for research purposes, the requirement for consent from study participants was waived. The study was registered at the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (register number EUPAS31571), where the study protocol was deposited.

A hypothetical target trial was emulated in which eligible individuals received PPIs or no PPIs. Eligible individuals were those aged 40 years or older with at least 1 year of continuously insured records before and after study entry, who did not meet the exclusion criteria (Table 1).

The primary treatment strategy to be compared was an initiation of any PPI (ATC codes A02BC01-06) at baseline and non-initiation. PPI use was assessed using prescriptions dispensed by community pharmacies and applying 365 days of washout period. Information on in-hospital use or over-the-counter (OTC) PPI use was not available. Based on the treatment guideline, patients usually initiate standard-dose therapy for 4–8 weeks (28–56 defined daily doses [DDDs]) and then extend use [22]. Hence, a consecutive use of 56 DDDs was set as a requirement to assign PPI initiators (for details on the DDD computation, see Table S1) [23]. The first PPI dispensing date formed the index date for each individual in the PPI initiator group. Consecutive treatment was assumed if the initiator filled the next prescription no later than 30 days from the expected dispensing day.

Individuals who were eligible as PPI initiators ($n = 674,544$) were followed up and compared to non-initiators (Figure S1). To minimize the selection bias in the group of non-initiators, the approach of creating a series of trials was applied. Each individual had several trials with different enrollment points, that is, every quarter of the year from when they became eligible to the end of study participation

TABLE 1 Study design of the emulated trial using claims data

	A hypothetical clinical controlled trial	Emulated trial using claims data
Eligibility criteria	<ul style="list-style-type: none"> • Adult individuals (≥ 40 years at baseline) • The duration of the enrollment period is determined based on the required sample size and recruitment period • No prescription of PPI in the previous 365 days • No prior history of dementia 	The same, except that only participants with at least 1 year of continuously insured records before and after study entry are eligible
Treatment strategies	Two treatment strategies are considered: (1) receive continuous PPI treatment of 56 DDDs or more at baseline and remain on PPI during the follow-up (2) no initiation of PPI use during the follow-up	The same, except that an individual in the initiator group is allowed to stop taking PPI depending on medical condition
Randomized assignment	Individuals will be randomly assigned to either strategy at baseline without blinding	Individuals are assumed to be randomly assigned at baseline within levels of age, sex, German nationality, hospitalizations in the year preceding cohort entry, history of obesity, diabetes, hypertension, heart disease, peripheral vascular disease, coagulopathy, chronic pulmonary disease, cancer, depression, abuse of substances or psychosis, diseases that may cause dementia, cerebrovascular disease, inflammation, infection or injury of the nervous system, use of medication (antidiabetics, antihypertensives, statins, clopidogrel, anticholinergics, anti-inflammatory drugs, corticosteroids, antidepressants and psycholeptics)
Start/end of follow-up	Follow-up starts at treatment assignment and ends at first occurrence of an outcome, death, loss to follow-up or administrative end of the study, whichever comes first	The same
Outcome	Diagnosis of dementia	The same (two records in consecutive quarters needed)
Analysis plan	Intention-to-treat analysis	Intention-to-treat analysis with adjustment for baseline covariates

[24]. All individuals' trials were pooled in the emulated trials of non-initiators, as long as they met the eligibility as study participants but had not yet initiated PPI intake [24]. Three times the number of initiators ($n = 2,023,632$) were then randomly selected from the trials of the non-initiators, applying an exposure density sampling method that matches for cohort entry time (the same quarter of the year) [25].

The primary outcome of interest was incident dementia (ICD-10 codes F00, F01, F03, F05.1, G30, G31.0, G31.1, G31.9 and F02.8+G31.82) (Table S2) [26]. To ascertain the incidence of dementia, the ICD-10 codes for dementia had to be found at least twice in consecutive quarters. Unspecified dementia, Alzheimer's disease (AD) and vascular dementia (VaD) were differentiated for additional subtype analyses.

Confounding factors

Our analyses were adjusted for potential confounding factors, considering direct causes of PPI use or dementia or both, excluding possible instrumental variables [27]. Participants' baseline

characteristics were measured during the 180 days before, including the index date. Comorbidity was assessed, categorizing obesity, diabetes, hypertension, heart disease, peripheral vascular disease, coagulopathy, chronic pulmonary disease, cancer, depression, abuse of substances or psychosis, cerebrovascular disease, diseases that may cause dementia, inflammation, infection or injury of the nervous system assuming that these conditions are risk factors for dementia. These conditions were defined according to a coding algorithm proposed by Quan et al. [28] Concurrent intake of antidiabetics, antihypertensives, statins, clopidogrel, anticholinergics, anti-inflammatory drugs, corticosteroids, antidepressants and psycholeptics was also included as covariates (Table S3).

Statistical analysis

Weighted Cox regression models were used to estimate the effect of PPI initiation versus non-initiation on dementia risk. Entropy balancing was used to adjust for baseline confounding [29,30]. To reduce the potential for reverse causality, additional analyses were performed, where dementia cases occurring during the first 1, 3 and

5 years of follow-up, respectively, were censored. Based on this, an adjusted cumulative hazard curve was drawn that compares the hazard at different times over the observation period.

Weighted pooled logistic regression models were used to examine the effect of time-varying PPI use on dementia risk, because PPI intake varied over time [31,32]. Time-varying stabilized inverse probability weights were used to adjust for the time-varying confounding. A dataset was constructed with follow-up intervals of 180 days and updated weights. To additionally adjust for time-varying selection bias, each individual at each time t was weighted by the inverse probability of being censored due to incidence of dementia, death or end of study participation. This approach provides a conservative estimate of the HR, analogous to analysis in an unblinded RCT, and can be considered as an intention to continuous PPI treatment analysis [31]. A survival curve standardized for baseline covariate distribution and weighted for time-varying confounders was also drawn.

Several sensitivity analyses were performed to examine the extent to which observed associations could be due to bias. As the first sensitivity analysis, the same weighted Cox model restricted to individuals who had an ICD code of the approved indications as documented in the official product information (gastroesophageal reflux disease, *Helicobacter pylori* infection, peptic ulcer, esophagitis, Zollinger–Ellison syndrome and heartburn) was fitted [33]. This restriction strategy aims to make patients more homogeneous regarding potential confounding factors and treatment effects [34–36]. Additionally PPI initiation was compared to the initiation of an active comparator, histamine 2 receptor antagonists (H2RAs) (ATC: A02BA01-08) [36]. Like a PPI initiator, an H2RA initiator was defined as a person who fulfilled consecutive use episodes with at least 56 DDDs.

Lastly, an E -value was calculated, which indicates the minimum strength of an association that an unmeasured confounder would need to have to account for the observed association between PPI exposure and incidence of dementia [37]. Analyses were performed using R (version 3.6.3).

RESULTS

In all, 674,544 PPI initiators and 2,023,632 non-initiators who met the eligibility criteria in our dataset of 6,097,740 individuals were identified. The median follow-up time of PPI initiators and non-initiators was 4.3 years (interquartile range [IQR] 2.3–6.8) and 5.3 years (IQR 3.0–7.5), respectively. The median age of the whole study population was 56.0 years (IQR 48.0–68.0), and 49% were women. More details on the demographic and clinical characteristics of PPI initiators and non-initiators are provided in Table S4. In our dataset, PPI initiators generally had more baseline diseases and medication intake history. After weighting, however, both groups were well balanced on the confounders (Table 2).

Of 2,698,176 individuals, there were 39,776 cases of dementia in PPI initiators (5.9%) and 31,042 cases in non-initiators (1.5%) (Table 3). With a 1-year lag window application, the incidence of

dementia decreased to 29,746 cases (4.4%) in PPI initiators and 26,830 cases (1.3%) in non-initiators. Without application of a lag window, the HR for comparing the overall dementia risk in PPI initiators and non-initiators was 1.71 (95% CI 1.67–1.75). HRs for PPI initiation versus non-initiation slightly decreased after censoring cases that occurred during the first 1, 3 and 5 years of follow-up, respectively (Table 3).

Whilst there was more dementia incidence during the first year in PPI initiators ($n = 10,030$, 25% of total cases) than in non-initiators ($n = 4212$, 14% of total cases) and the adjusted cumulative hazard curves diverged promptly with the start of follow-up (not shown), gradual diverging of curves was observed when a 1-year lag window was applied (Figure 1), which is pathologically more plausible for dementia.

In the analysis of time-varying PPI use versus non-use that considered time-varying confounding and censoring, increased dementia risk was observed by PPI use (HR 1.56, 95% CI 1.50–1.63; 1-year lag window applied) (Table 4). The survival curves standardized for baseline covariates and weighted for time-varying confounders also showed that PPI use had a higher risk of dementia than no PPI use (Figure S2).

In the sensitivity analysis restricted to 193,513 initiators and 32,974 non-initiators who had at least one on-label PPI indication, baseline characteristics of both groups were similar even before weighting, and a better balance was observed after weighting (Table S5). Again, an increased risk of dementia by PPI initiation versus non-initiation was found (HR 1.32, 95% CI 1.23–1.42; 1-year lag window applied) (Table 4).

On the other hand, the comparison of 660,635 PPI initiators and 9457 H2RA initiators identified 28,803 and 585 dementia cases in the two groups with no difference concerning the risk of dementia (HR 0.93, 95% CI 0.85–1.01; 1-year lag window applied). The demographic and clinical characteristics of the groups are provided in Table S6.

E -value analysis for the primary analysis suggested that an unobserved confounder would need to be associated with PPI initiation and dementia risk with a relative risk (RR) of 2.45, above and beyond the adjusted confounders, to explain the observed HR of 1.54. An unobserved confounder would need to be related with an RR of 2.39 with PPI initiation and dementia to shift the lower CI limit (i.e., 1.51) to the null.

There were no notable differences in risks of dementia subtypes associated with PPI initiation and time-dependent use (Table 5).

DISCUSSION

The present study is the first to emulate a hypothetical randomized trial of PPI use and incident dementia, suggesting that PPI initiation increases the risk of dementia. Even after the long lag-window application for controlling reverse causality [8,9], an increased risk of dementia by PPI initiation and its long-term use was observed. An analysis of time-dependent PPI intake adjusted for time-varying

TABLE 2 Comparison of baseline confounders for initiators of PPIs and non-initiators before/after weighting

	Unweighted population			Weighted population		
	PPI initiators	Non-initiators	SD	PPI initiators	Non-initiators	
	674,544	2,023,632		674,544	2,022,950	
Age (years)	62.8 (13.2)	56.9 (12.4)	0.463	58.4 (12.9)	58.3 (12.9)	<0.001
Women (n, %)	370,897 (55.0)	951,709 (47.0)	0.160	330,591 (49.0)	991,675 (49.0)	<0.001
German nationality (n, %)	577,458 (85.6)	1,525,175 (75.4)	0.261	525,651 (77.9)	1,576,366 (77.9)	<0.001
Hospitalizations in the year preceding cohort entry	53,202 (7.9)	11,968 (0.6)	0.368	16,381 (2.4)	48,515 (2.4)	0.002
Obesity	107,752 (16.0)	94,233 (4.7)	0.379	50,651 (7.5)	151,728 (7.5)	<0.001
Diabetes	153,848 (22.8)	136,341 (6.7)	0.465	72,842 (10.8)	218,465 (10.8)	<0.001
Hypertension	356,005 (52.8)	336,079 (16.6)	0.821	173,652 (25.7)	520,346 (25.7)	<0.001
Heart disease	152,897 (22.7)	107,072 (5.3)	0.518	65,355 (9.7)	195,601 (9.7)	0.001
Peripheral vascular disease	74,725 (11.1)	48,837 (2.4)	0.351	31,138 (4.6)	93,036 (4.6)	0.001
Coagulopathy	17,765 (2.6)	9801 (0.5)	0.174	6899 (1.0)	20,570 (1.0)	0.001
Chronic pulmonary disease	135,390 (20.1)	106,621 (5.3)	0.456	60,914 (9.0)	182,277 (9.0)	0.001
Cancer	65,582 (9.7)	42,338 (2.1)	0.328	27,151 (4.0)	81,323 (4.0)	<0.001
Depression	152,131 (22.6)	115,990 (5.7)	0.497	67,334 (10.0)	201,667 (10.0)	<0.001
Abuse of substances or psychosis	16,000 (2.4)	16,251 (0.8)	0.126	8069 (1.2)	24,229 (1.2)	<0.001
Diseases may cause dementia	92,855 (13.8)	88,348 (4.4)	0.332	45,602 (6.8)	136,645 (6.8)	<0.001
Cerebrovascular disease	75,552 (11.2)	47,363 (2.3)	0.358	30,968 (4.6)	92,482 (4.6)	0.001
Inflammation, infection or injury in nervous system	18,310 (2.7)	13,813 (0.7)	0.158	8097 (1.2)	24,328 (1.2)	<0.001
Antihypertensive drugs	375,188 (55.6)	340,175 (16.8)	0.883	179,549 (26.6)	537,916 (26.6)	0.001
Anti-inflammatory drugs	334,716 (49.6)	200,353 (9.9)	0.965	134,087 (19.9)	401,659 (19.9)	0.001
Statins	137,488 (20.4)	101,273 (5.0)	0.475	59,915 (8.9)	179,495 (8.9)	<0.001
Antidiabetic drugs	92,826 (13.8)	82,959 (4.1)	0.344	44,106 (6.5)	132,280 (6.5)	<0.001
Antidepressants	68,568 (10.2)	45,502 (2.2)	0.333	28,642 (4.2)	85,637 (4.2)	0.001
Psycholeptics	62,812 (9.3)	38,919 (1.9)	0.325	25,530 (3.8)	76,389 (3.8)	<0.001
Corticosteroids	57,267 (8.5)	21,817 (1.1)	0.353	19,800 (2.9)	58,938 (2.9)	0.001
Anticholinergics	44,144 (6.5)	30,722 (1.5)	0.258	18,768 (2.8)	56,151 (2.8)	<0.001
Clopidogrel	21,259 (3.2)	6220 (0.3)	0.219	6867 (1.0)	20,246 (1.0)	0.002

Note: Data are mean (standard deviation) or n (percentage).

Abbreviations: PPI, proton pump inhibitor; SD, standardized difference.

confounding and censoring further supported an increased risk of dementia.

A positive association was also found between PPI initiation and dementia risk in the extreme restriction analysis limited to persons with on-label indications for PPI prescription to make treatment groups more comparable concerning potential confounding [35,36]. In this analysis, there was overlap in pretreatment demographics and clinical characteristics of PPI initiators and non-initiators (Table S5), and thereby our finding is strengthened. Besides, our finding is consistent with the result of a recent study that compared dementia risk by PPI intake versus no intake in patients with upper gastrointestinal disease (HR 1.89, 95% CI 1.38–2.58, $p < 0.001$) [6].

An analysis for comparing the dementia risk in PPI and H2RA initiators was further performed. Although no difference in the


risk of dementia between PPI initiators and H2RA initiators was observed, our finding was consistent with studies that reported no difference in the dementia risk between PPI users and H2RA users: (1) Park et al. (2019) (incidence rate ratio 1.01, 95% CI 0.96–1.06) [38]; (2) Wu et al. (2020) (HR 0.82, 95% CI 0.58–1.17) [4]. There are few studies on the risk of dementia by H2RA use versus non-use. Nevertheless, several studies reported an increased risk of dementia by H2RA use versus non-use: (1) Hwang et al. (2018) (HR 1.31, 95% CI 1.13–1.51) [39]; (2) Lin et al. (2021) (HR 1.36, 95% CI 1.10–1.68) [6]; (3) Chen et al. (2020) (HR 1.84, 95% CI 1.49–2.20) [2] and (4) Boustani et al. (2007) (odds ratio 2.42, 95% CI 1.17–5.04) [40]. Thus, it is questionable whether H2RA is a valid active comparator since its positive safety profile is not established [41,42].

TABLE 3 Effect of PPI initiation on overall dementia risk

	Number of events in PPI initiators	Number of events in non-initiators	HR (95% CI)	p
No lag window	39,776	31,042	1.71 (1.67–1.75)	<2e-16
1-year lag window applied	29,746	26,830	1.54 (1.51–1.58)	<2e-16
3-year lag window applied	15,840	17,173	1.45 (1.41–1.50)	<2e-16
5-year lag window applied	6651	8581	1.38 (1.32–1.44)	<2e-16

Note: Hazard ratios (HRs) were adjusted for age, sex, German nationality, hospitalizations in the year preceding cohort entry, history of obesity, diabetes, hypertension, heart disease, peripheral vascular disease, coagulopathy, chronic pulmonary disease, cancer, depression, abuse of substances or psychosis, diseases that may cause dementia, cerebrovascular disease, inflammation, infection or injury of the nervous system, use of antidiabetics, antihypertensives, statins, clopidogrel, anticholinergics, anti-inflammatory drugs, corticosteroids, antidepressants and psycholeptics.

Abbreviations: CI, confidence interval; HR, hazard ratio; PPI, proton pump inhibitor.

**FIGURE 1** Cumulative hazard curve adjusted for baseline covariates**TABLE 4** Additional analyses for comparison with the effect of PPI initiation on dementia risk using different analysis approaches

	Number of events in PPI initiators	Number of events in non-initiators	HR (95% CI)	p
PPI time-varying use vs. non-use ^a	29,746	26,830	1.56 (1.50–1.63)	2e-16
PPI initiation vs. non-initiation (restricted) ^b	6,996	1,179	1.32 (1.23–1.42)	4.54e-14

Note: Hazard ratios (HRs) were adjusted for age, sex, German nationality, hospitalizations in the year preceding cohort entry, history of obesity, diabetes, hypertension, heart disease, peripheral vascular disease, coagulopathy, chronic pulmonary disease, cancer, depression, abuse of substances, diseases that may cause dementia, cerebrovascular disease, inflammation, infection or injury of the nervous system, use of antidiabetics, antihypertensives, statins, clopidogrel, anticholinergics, anti-inflammatory drugs, corticosteroids, antidepressants and psycholeptics.

Abbreviations: CI, confidence interval; HR, hazard ratio; PPI, proton pump inhibitor.

^aUsing weighted pooled logistic regression with adjustment for all covariates listed above and follow-up time (180-day interval) and its square term. A 1-year lag window between exposure and outcome was applied.

^bPPI initiation effect on dementia risk (within the individuals who had any PPI indication at the baseline. PPI indications included gastroesophageal reflux disease, *Helicobacter pylori* infection, peptic ulcer, esophagitis, Zollinger–Ellison syndrome and heartburn). A 1-year lag window between exposure and outcome was applied.

A previous meta-analysis by Zhang et al. [11] suggested that PPI use elevates the risk of dementia (HR 1.29, 95% CI 1.12–1.49). A strength of this analysis is that no cross-sectional studies were included. Therefore, the bias by reverse causation or long latent period of dementia could be minimized compared to other systematic

reviews that included cross-sectional studies in their meta-analyses [10,12,43].

Whilst Khan et al. [10] performed a meta-analysis including five further studies compared to the meta-analysis by Zhang et al., all the additionally included studies found no association between PPI

TABLE 5 Effect of PPI initiation and time-updated use of PPI on the risk of dementia subtypes

	Number of events in PPI initiators	Number of events in non-initiators	Initiation effect ^a		Time-varying use effect ^b	
			HR (95% CI)	p	HR (95% CI)	p
Unspecified dementia	18,371	16,519	1.55 (1.51–1.59)	<2e–16	1.52 (1.45–1.60)	<2e–16
AD	4608	4424	1.52 (1.44–1.61)	<2e–16	1.47 (1.34–1.62)	<2e–16
VaD	6166	5223	1.53 (1.45–1.61)	<2e–16	1.70 (1.56–1.85)	<2e–16

Note: Hazard ratios (HRs) were adjusted for age, sex, German nationality, hospitalizations in the year preceding cohort entry, history of obesity, diabetes, hypertension, heart disease, peripheral vascular disease, coagulopathy, chronic pulmonary disease, cancer, depression, abuse of substances or psychosis, diseases that may cause dementia, cerebrovascular disease, inflammation, infection or injury in nervous system, use of antidiabetics, antihypertensives, statins, clopidogrel, anticholinergics, anti-inflammatory drugs, corticosteroids, antidepressants and psycholeptics.

Abbreviations: AD, Alzheimer's disease; CI, confidence interval; HR, hazard ratio; PPI, proton pump inhibitor; VaD, vascular dementia.

^aA 1-year lag window between exposure and outcome was applied.

^bUsing weighted pooled logistic regression with adjustment for all covariates listed above and follow-up time (180-day interval) and its square term. A 1-year lag window between exposure and outcome was applied.

use and dementia risk. However, they included relatively older study populations (mean or median age over 80 years). In these older study participants, a lack of association between PPI use and dementia might have resulted from competing risk by death, that is, they were at greater risk of dying earlier than being diagnosed with dementia [8]. Likewise, although the latest review by Wang et al. [12] contained the largest number of study participants, cross-sectional studies were included in the quantitative synthesis. This meta-analysis did not provide subgroup analysis stratified by study quality or study design.

The effect of a frequently prescribed medication is often of interest in healthcare studies. However, estimating a medication's effect can be challenging because it requires enrollment of participants without prevalent disease and long-term follow-up [19,20]. To the best of our knowledge, only one RCT has been performed regarding dementia risk by PPI use, and it reported no association between pantoprazole use and dementia risk [44]. However, the main objective for pantoprazole randomization was to determine whether pantoprazole use reduces the risk of gastrointestinal tract complications in participants receiving antithrombotic therapy. Dementia was one amongst several secondary outcomes that were additionally observed. Furthermore, this trial had only a median of 3-years follow-up time with a very small number of reported dementia cases ($n = 101$, 0.6%), and the assured washout period was 30 days. To overcome the challenges in conducting RCTs, advantage was taken of the rich data from a large insurer, mitigating several limitations of previous observational studies on this topic [19].

The association between PPI initiation and its time-dependent use and dementia risk was also seen in our subtype analysis. In our data, unspecified dementia was most frequently observed, followed by VaD and AD, whilst it has been reported that AD is the most common type of dementia, consisting of about 60% of dementia cases [45]. Although 6% of individuals diagnosed with dementia had ICD-10 codes of both AD and VaD in our dataset, mixed dementia is not considered in the ICD-10 coding system. Therefore, the same analysis was repeated applying the different subtype classifications, including mixed dementia (Figures S3 and S4), and no notable change in the result was observed (Table S7). In ICD-11, the latest version of the ICD to be adopted from 2022, the code 6D80.2 is available with a description "Alzheimer disease dementia, mixed

type, with cerebrovascular disease" [46]. This new code would be beneficial for better classification of subtypes in future studies using claims data, given dementia is often associated with several mixed pathologies [45].

Dementia includes a set of diseases with common clinical symptoms and several plausible pathophysiological mechanisms of brain deterioration in which PPIs may be involved, such as increased amyloid- β plaques, increased tau protein formation and vitamin B12 deficiency [47]. Furthermore, a recent study showed how PPIs could inhibit the activity of the core-cholinergic enzyme, with potencies that lie far below their in vivo plasma and cerebrospinal fluid concentration in humans even at low dosages [13]. This finding is significant because degeneration of the cholinergic neuronal network is a paramount feature of neurodegenerative diseases that commonly lead to the manifestation of cognitive impairment [48]. Our finding, together with this discovered mechanism, warrants further pathophysiological studies on PPIs in relation to the incidence of dementia.

Despite the use of rigorous statistical approaches to mitigate bias in the design of nonrandomized studies, there could be residual confounding. Limited information on lifestyle factors such as obesity and alcohol abuse was available solely as relevant ICD-10 codes. No information on socioeconomic status or data on genetic risk such as education level or family history of dementia was available.

In our additional analysis to examine bias by unmeasured confounding, an E -value of 2.45 was obtained, which indicates that an unmeasured confounder associated with both PPI initiation and incidence of dementia would have to have an effect as large as 2.45 beyond the measured confounders, to explain away the estimate. For instance, although an association of saturated fat intake with risk of AD (RR 1.87, 95% CI 1.09–3.20) has been reported, this confounder could not be taken into account due to a lack of dietary information in our data [49]. Occupational factors such as shift work were not assessed either, whilst previous studies have shown that shift work could increase the risks of dementia (HR range 1.12–2.43) [50]. Although each unmeasured dementia risk factor is not presumed to have an RR larger than the calculated E -value, the observed effect estimate could be smaller if the analysis is additionally adjusted for lifestyle-relevant factors.

Regarding the exposure measurement, PPI use was assessed using prescriptions dispensed by community pharmacies. Information on in-hospital use and use as an OTC drug was not available in the data source. Thus, some PPI users might have been included in the non-initiator group. Whilst exposure to PPIs might be underestimated due to OTC use, PPIs might also be overestimated when prescribed "on-demand". Moreover, no information on patient compliance was available. Overall, the combined influence of sources of exposure measurement error is expected to be independent of the outcome of interest and therefore attenuated towards the null. Classifying different subtypes of dementia in our dataset was also difficult as many individuals were diagnosed with multiple types of dementia. This study did not evaluate the effects of individual PPI agents because of the complexity of dispensing episodes, for example switching between different PPI agents, prescriptions of different agents at the same time, or within very short intervals in one patient.

CONCLUSION

The present study showed a positive association between PPI use and dementia risk in the general population. Our study contributes to achieving a consensus on estimating the effect of PPI use on dementia risk by mitigating typical biases occurring in observational studies. However, due to the complexities of dementia subtype classification, studies taking clear criteria into account for diagnosis are needed to determine the causation between PPI use and dementia subtypes.

ACKNOWLEDGEMENT

Open access funding enabled and organized by ProjektDEAL.

CONFLICT OF INTEREST

The authors declare no competing interests.

AUTHOR CONTRIBUTIONS

Nayeon Ahn: Conceptualization (lead); formal analysis (lead); investigation (lead); methodology (lead); writing—original draft (lead); writing—review and editing (lead). Michael Nolde: Conceptualization (supporting); formal analysis (supporting); methodology (supporting); writing—review and editing (supporting). Alexander Günter: Data curation (equal); writing—review and editing (supporting). Florian Güntner: Data curation (equal); writing—review and editing (supporting). Roman Gerlach: Data curation (equal); writing—review and editing (supporting). Martin Tauscher: Data curation (equal); writing—review and editing (supporting). Ute Amann: Conceptualization (supporting); methodology (supporting); writing—review and editing (supporting). Jakob Linseisen: Conceptualization (supporting); methodology (supporting); writing—review and editing (supporting). Christa Meisinger: Conceptualization (supporting); methodology (supporting); writing—review and editing (supporting). Ina-Maria Rückert-Eheberg: Conceptualization (supporting); methodology (supporting); project administration (equal); writing—review and editing (supporting). Sebastian E. Baumeister: Conceptualization

(supporting); funding acquisition (lead); methodology (supporting); project administration (equal); writing—original draft (supporting); writing—review and editing (supporting).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from Allgemeine Ortskrankenkassen Bayern by contractual agreement.

ORCID

Nayeon Ahn  <https://orcid.org/0000-0003-4414-114X>

Michael Nolde  <https://orcid.org/0000-0001-6893-7367>

REFERENCES

1. Lassalle M, Le Tri T, Bardou M, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. *Eur J Clin Pharmacol*. 2020;76:449-457.
2. Chen LY, Lin HJ, Wu WT, et al. Clinical use of acid suppressants and risk of dementia in the elderly: a pharmaco-epidemiological cohort study. *Int J Environ Res Public Health*. 2020;17:8271.
3. Torres-Bondia F, Dakterzada F, Galván L, et al. Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias. *Sci Rep*. 2020;10:21046.
4. Wu CL, Lei WY, Wang JS, Lin CE, Chen CL, Wen SH. Acid suppressants use and the risk of dementia: a population-based propensity score-matched cohort study. *PLoS One*. 2020;15:e0242975.
5. Weiss A, Gingold-Belfer R, Boltin D, et al. Chronic omeprazole use in the elderly is associated with decreased risk of dementia and cognitive decline. *Dig Liver Dis*. 2021;S1590-8658(21)00884-7. doi:10.1016/j.dld.2021.11.018. Online ahead of print.
6. Lin H-C, Huang K-T, Lin H-L, et al. Use of gastric acid-suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: a population-based retrospective cohort study. *PLoS One*. 2021;16(3):e0249050.
7. Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. *N Engl J Med*. 2020;382:674-678.
8. Weuve J, Proust-Lima C, Power MC, et al. Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. *Alzheimers Dement*. 2015;11(9):1098-1109.
9. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. *Ann Neurol*. 2008;64:492-498.
10. Khan MA, Yuan Y, Iqbal U, et al. No association linking short-term proton pump inhibitor use to dementia: systematic review and meta-analysis of observational studies. *Am J Gastroenterol*. 2020;115:671-678.
11. Zhang Y, Liang M, Sun C, et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. *Eur J Clin Pharmacol*. 2019;76:139-147.
12. Wang H, Tian L, Yan X. No association between acid suppressant use and risk of dementia: an updated meta-analysis. *Eur J Clin Pharmacol*. 2021;78(3):375-382. doi:10.1007/s00228-021-03248-0
13. Kumar R, Kumar A, Nordberg A, Långström B, Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—a plausible missing link for their association with incidence of dementia. *Alzheimers Dement*. 2020;16:1031-1042.
14. Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. *Int Psychogeriatr*. 2016;28:1059-1065.
15. Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar L. Proton pump inhibitors and risk of mild cognitive impairment and dementia. *J Am Geriatr Soc*. 2017;65:1969-1974.

16. Ahn N, Frenzel S, Wittfeld K, et al. Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study. *Eur J Clin Pharmacol*. 2021;77:1039-1048.
17. Imfeld P, Bodmer M, Jick SS, Meier CR. Proton pump inhibitor use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis. *Drug Saf*. 2018;41:1387-1396.
18. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer's disease. *Am J Gastroenterol*. 2017;112:1802-1808.
19. Gill J, Prasad V. Improving observational studies in the era of big data. *Lancet*. 2018;392:716-717.
20. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol*. 2016;183:758-764.
21. Pazzagli L, Linder M, Zhang M, et al. Methods for time-varying exposure related problems in pharmacoepidemiology: an overview. *Pharmacoepidemiol Drug Saf*. 2018;27:148-160.
22. Koop H, Fuchs KH, Labenz J, et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. *Z Gastroenterol*. 2014;52:1299-1346.
23. WHO Collaborating Centre for Drug Statistics Methodology [updated 14.12.2021]. https://www.whocc.no/atc_ddd_index/?code=A02BC. Accessed January 26, 2022.
24. Danaei G, Rodriguez LA, Cantero OF, Logan R, Hernán MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. *Stat Methods Med Res*. 2013;22:70-96.
25. Ohneberg K, Beyersmann J, Schumacher M. Exposure density sampling: dynamic matching with respect to a time-dependent exposure. *Stat Med*. 2019;38:4390-4403.
26. Zentralinstitute für die Kassenärztliche Versorgung in Deutschland. Demenz Zi-Kodier_Manual 2020. https://www.zi.de/fileadmin/images/content/Kodierhilfe/Kodiermanual_Demenz.pdf. Accessed January 26, 2022.
27. VanderWeele TJ. Principles of confounder selection. *Eur J Epidemiol*. 2019;34:211-219.
28. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43:1130-1139.
29. Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. *Polit Anal*. 2012;20:25-46.
30. Matschinger H, Heider D, König HH. A comparison of matching and weighting methods for causal inference based on routine health insurance data, or: what to do if an RCT is impossible. Ein vergleich von "matching" und "weighting"—Verfahren zur Kausalanalyse mit Routinedaten von Krankenversicherungen, oder: was tun wenn ein RCT nicht möglich ist. *Gesundheitswesen*. 2020;82:S139-S150.
31. Fewell Z, Hernán MA, Wolfe F, Tilling K, Choi H, Sterne JAC. Controlling for time-dependent confounding using marginal structural models. *Stata J*. 2004;4(4):402-420. doi:10.1177/1536867X0400400403
32. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology*. 2000;11:561-570.
33. European Medicines Agency. Questions and answers on the referral for Protiium and associated names 2010. https://www.ema.europa.eu/en/documents/referral/questions-answers-referral-protiium-associated-names-pantoprazole-20-40-mg-gastro-resistant-tablets_en.pdf. Accessed January 26, 2022.
34. Secrest MH, Platt RW, Dormuth CR, et al. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. *Pharmacoepidemiol Drug Saf*. 2020;29(Suppl 1):26-34.
35. Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. *Med Care*. 2007;45(10 Supl 2):S131-S142.
36. D'Arcy M, Stürmer T, Lund JL. The importance and implications of comparator selection in pharmacoepidemiologic research. *Curr Epidemiol Rep*. 2018;5:272-283.
37. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med*. 2017;167:268-274.
38. Park SK, Nam JH, Lee H, Chung H, Lee EK, Shin JY. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia. *J Gastroenterol Hepatol*. 2019;34:2135-2143.
39. Hwang IC, Chang J, Park SM. A nationwide population-based cohort study of dementia risk among acid suppressant users. *Am J Geriatr Psychiatry*. 2018;26:1175-1183.
40. Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. *J Am Geriatr Soc*. 2007;55:1248-1253.
41. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. *Nat Rev Rheumatol*. 2015;11:437-441.
42. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 9). https://www.encepp.eu/standards_and_guidances/documents/1.ENCePPMethodsGuideRev.9.pdf. Accessed January 26, 2022.
43. Wijarnpreecha K, Thongprayoon C, Panjawanat P, Ungprasert P. Proton pump inhibitors and risk of dementia. *Ann Transl Med*. 2016;4:240.
44. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. *Gastroenterology*. 2019;157:682-691.e2.
45. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer's and vascular types. *Biomed Res Int*. 2014;2014:908915.
46. ICD-11 for Mortality and Morbidity Statistics (MMS) 2020 [updated 05.2021]. <https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1543494610>. Accessed January 26, 2022.
47. Ortiz-Guerrero G, Amador-Munoz D, Calderon-Ospina CA, López-Fuentes D, Nava-Mesa MO. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. *Neural Plast*. 2018;2018:5257285.
48. Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. *Pharmacol Biochem Behav*. 2011;99:254-261.
49. Cao GY, Li M, Han L, et al. Dietary fat intake and cognitive function among older populations: a systematic review and meta-analysis. *J Prev Alzheimers Dis*. 2019;6:204-211.
50. Leso V, Caturano A, Vetrani I, Iavicoli I. Shift or night shift work and dementia risk: a systematic review. *Eur Rev Med Pharmacol Sci*. 2021;25:222-232.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Ahn N, Nolde M, Günter A, et al. Emulating a target trial of proton pump inhibitors and dementia risk using claims data. *Eur J Neurol*. 2022;29:1335-1343. doi:[10.1111/ene.15284](https://doi.org/10.1111/ene.15284)

MANAGE-PD

Tool for Making Informed Decisions to
Aid Timely Management of Parkinson's Disease



MANAGE-PD allows you to:

- Identify PD patients inadequately controlled on oral medications
- Determine which patients with PD may be adequately controlled on their current treatment regimen or may require changes to their treatment regimen



Scan the QR code to
access to the web

Click here to
access to the web



MANAGE-PD is an AbbVie Inc. registered Medical Device. It is a collaborative research and development effort between AbbVie Medical Affairs and Health Economics and Outcomes, the Parkinson's Foundation and an international panel of Movement Disorder Specialists.

©2022 AbbVie Inc. All rights reserved. The Parkinson's Foundation logo is the sole property of the Parkinson's Foundation used with written permission. Any use of the Parkinson's Foundation name or logo without Foundation permission is prohibited. All content in <https://www.managepd.eu/> is intended only for informational use by healthcare professionals and is not offered as or intended to be medical advice for any particular patient. This information is not intended for patients. Only a healthcare professional exercising independent clinical judgement can make decisions regarding appropriate patient care and treatment options considering the unique characteristics of each patient.

PD: Parkinson's Disease